drugset

drugset / Trial / NCT03499119

AMG 334 20160172 Pediatric Migraine PK Study.

NCT03499119 ↗

Phase 1 Completed 53 enrolled Amgen

RandomizedParallel-groupOpen-labelBasic science

Summary

AMG 334 20160172 Pediatric Migraine PK Study.

Timeline

Start: 2018-05-04
Primary completion: 2021-11-23
Completion: 2021-11-23

Publications

Background Hershey AD, Paiva da Silva Lima G, Pannacciulli N, Mackowski M, Koukakis R, McVige JW. Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study. Clin Transl Sci. 2024 Mar;17(3):e13755. doi: 10.1111/cts.13755.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	—	—

Indications